Luisana Molina

la memoria de lo pasado y la previsión del porvenir, vale decir, el tiempo". JB

00m.in/qBfXw Our review article on perioperative immunotherapy has just been published in the new English-language journal of the Japan Lung Cancer Society I would very much welcome your comments, criticisms, and discussion.

This is the algorithm we touched on/walked through during our discussion with @rutikamehtaMD for Her2+ GEJ/Gastric adenocarcinoma! #OncTwitter #MedTwitter @gotoPER

High rates of burnout among early-career thoracic oncology faculty were just presented at #NACLC2025—this isn’t a personal failure, it’s a systemic problem. Long hours, emotional load, and constant pressure are taking a toll. @ASridharMD @AnaVManana @IASLC

Es #NETCancerDay Los #tumoresneuroendocrinos🦓 pueden presentar síntomas similares a gastritis, ansiedad, asma, síndrome intestino irritable… Colabora en su conocimiento y visibilidad para su diagnóstico precoz. Info👉 @Netespana @GrupoGetne @NETsMexico👇

Delhi’s AQI today: >400. That’s not “bad air.” That’s smoking 25 cigarettes a day - even if you’ve never touched one. 🚬💨 This #LungCancerAwarenessMonth, remember: ☠️ Air pollution is one of the leading causes of lung cancer in people who’ve never smoked. And it’s rising fast across India’s cities. It’s not about lifestyle anymore - It’s about the air we breathe. 🌫️ 💬 Reply with your city & today’s AQI Let’s show what our lungs are fighting every day. #LungCancerAwarenessMonth #AQI #AirPollution #OncoTwitter #MedTwitter #LCSM @iArpitSpeaks @Prathkum @SauravDassss @AAPDelhi @INCIndia @RahulGandhi @mohitlaws @newslaundry @dhruv_rathee @TheDeshBhakt

Este lunes 10 noviembre es el día mundial de los Tumores Neuroendocrinos #netcancerday 🦓 Desde @GrupoGetne estamos organizando una edición muy especial de nuestro simposio anual, que celebra los 20 años del grupo cooperativo. Nos vemos en Madrid 20 y 21 de noviembre ‼️

This is for young oncologists across LATAM! 🌎 
Share your experiences and insights in this regional survey on the needs and challenges of young oncologists in Latin America. 🗳️ Take the survey
👉 docs.google.com/forms/d/e/1FAI… #Oncología #LATAMOncology

For an excellent overview of strain in #CardioOnc, check out this @JACCJournals primer 👇 jacc.org/doi/epdf/10.10…

Press release from monarchE: at the 7-year analysis, adjuvant abemaciclib significantly improved OS. Something we rarely see in the early-stage setting & which further reinforces the role of adjuvant CDK4/6 inhibitors for high-risk HR+/HER2- breast cancer. investor.lilly.com/news-releases/…

Consensus statement from Canadian thoracic oncologists @LungCaJournal on #ALK NSCLC. Supports adjuvant alectinib for resected stage Ib+ NSCLC, preference for first line lorlatinib over alectinib or brigatinib, chemotherapy post TKI and not immunotherapy. lungcancerjournal.info/article/S0169-…

Liver Segments: Axial CT and 3D Reconstruction Source: xray_iq

Muchas felicitaciones a los ganadores. conquer.org/news/acho-awar…

RECUERDA:

🔥 4-Year RELATIVITY-047 Update: Nivolumab + Relatlimab Combo in Advanced Melanoma 🔥 ✅ Confirmed PFS superiority over nivolumab alone (30.6% vs 23.6% at 4 years) ⏳ ✅ Clinically meaningful OS benefit (52.0% vs 42.8%) sustained, with improved melanoma-specific survival (59.7% vs 49.6%) 🎯 ✅ Higher ORR (43.9% vs 33.4%) supports enhanced tumor control 💪 ✅ Benefit persists despite grade 3-4 toxicities or treatment stops ⚠️ ✅ No new safety concerns after 4 years 🛡️ ✅ Lower toxicity compared to other IO combos like nivolumab+ipilimumab 🔥❌ 🌟 Significance: This durable efficacy with improved safety profile strengthens nivolumab + relatlimab as a preferred first-line immunotherapy in advanced melanoma—offering patients a better balance of long-term control and tolerability compared to older, more toxic combos. A game-changer for standard of care! 🏆🩺 #precisiononcology doi.org/10.1016/j.ejca…

15 profundas afirmaciones que cambiarán tu forma de pensar: 1.

Ultimate review on Reirradiation. All that you need to know in one place. Must read!! doi.org/10.3322/caac.7… @OncoAlert

Axillary Management After Neoadjuvant Systemic Therapy From Dr. Mediget Teshome's wonderful presentation👇 #ASCO25

First randomized trial testing circadian rhythm and time of immunotherapy administration show impressive results and some biological correlates open a research field in this setting #ASCO25 ⁦@OncoAlert⁩

🚨SPRING-01🚨 🔍Locally Advanced Rectal Cancer RCT: 25 Gy x 5 ➡️ CAPOX +- Sintilimab 🔥+ Sintilimab demonstrated: ✅⬆️pCR 59% vs 33% ✅No significant adverse surgical or safety signals Time to explore with organ preserving approaches⁉️ #ASCO25